Gilead Sciences

GILD · NASDAQ

$156.51+$3.44 (+2.25%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $153.07

Latest news

NewsOct 19, 2:07 PM ETVandana Singh
Gilead Bolsters Inflammatory Bowel Disease Pipeline With Promising Mid-Stage Trial Success
Press releaseOct 19, 8:00 AM ETBusiness Wire
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
Press releaseOct 15, 4:05 PM ETBusiness Wire
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
NewsOct 14, 12:58 PM ETVandana Singh
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
NewsOct 14, 8:40 AM ET
Vir Biotechnology Signs Up To $1.875B Gilead Deal For 3 Cancer Drug Candidates; Gilead To Pay $65M Cash Upfront And Buy 1,765,486 Shares At $14.16 Each, For A Total Of $25M, Plus Up To $1.785B In Milestones And Royalties
NewsOct 14, 8:34 AM ET
Vir Biotechnology Announces Collaboration, License Agreement With Gilead To Discover, Engineer Three PRO-XTEN Dual-Masked T-Cell Engager Development Candidates Targeting Selected Solid Tumor-Associated Antigens
NewsSep 30, 5:26 AM ETSnigdha Gairola
Bill Clinton Sounds Alarm on HIV Funding: ‘Cheaper Medicines Mean Nothing If They Never Reach People’
NewsSep 24, 1:35 PM ET
10 Health Care Stocks Whale Activity In Today’s Session
Press releaseSep 16, 8:30 AM ETBusiness Wire
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
Press releaseSep 15, 5:22 PM ETPRNewswire
ITOC Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against iTonic Holdings Ltd.
Press releaseSep 15, 11:10 AM ETBusiness Wire
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
Press releaseSep 15, 9:00 AM ETGlobe Newswire
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
Press releaseSep 8, 1:00 PM ETBusiness Wire
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
NewsAug 31, 1:38 PM ETVandana Singh
FDA Approves Gilead's New Single Tablet HIV Regimen
NewsAug 28, 12:43 PM ET
World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
Press releaseAug 27, 5:47 PM ETBusiness Wire
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
Press releaseAug 26, 4:05 PM ETBusiness Wire
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
Press releaseAug 26, 2:20 PM ETBusiness Wire
ITOC Stockholders Have Rights – If You Lost Money Investing in iTonic Holdings Ltd. Contact Robbins LLP for Information About Recovering Your Losses
NewsAug 24, 1:35 PM ET
10 Health Care Stocks Whale Activity In Today’s Session
Press releaseAug 24, 6:31 AM ETBusiness Wire
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
Press releaseAug 14, 6:15 PM ETPRNewswire
Did You Lose Money Investing in iTonic Holdings Ltd.? Robbins LLP Urges Investors With Significant Losses to Contact the Firm for Information About Their Rights Against ITOC
NewsAug 12, 8:44 AM ETAvi Kapoor
KLA, Snowflake, Airbnb And A Health Care Stock On CNBC’s ‘Final Trades’
Press releaseAug 7, 7:00 AM ETPRNewswire
PTHL Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against iTonic Holdings Ltd. (ITOC)- Previously Knowns as Pheton Holdings Ltd. (PTHL)
NewsAug 6, 3:41 AM ETTanya Rawat
Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'
NewsAug 4, 4:01 PM ET
Gilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate
Press releaseAug 4, 4:01 PM ETBusiness Wire
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
Press releaseAug 4, 4:01 PM ETBusiness Wire
Gilead Sciences Announces Second Quarter 2026 Financial Results
Press releaseAug 4, 2:49 PM ETBusiness Wire
Shareholder Alert: Robbins LLP Informs Shareholders of the iTonic Holdings Ltd. (ITOC)– Previously Known as Pheton Holdings Ltd. (PTHL)– Class Action Lawsuit
NewsAug 3, 3:30 PM ETKaustubh Bagalkote
SpaceX Could Swing $204 Billion After Earnings
NewsAug 3, 8:34 AM ETKaustubh Bagalkote
Eli Lilly Could Swing Over $76 Billion In Value After Earnings
NewsJul 28, 1:35 PM ET
4 Health Care Stocks With Whale Alerts In Today’s Session
NewsJul 28, 10:13 AM ETVandana Singh
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial
NewsJul 24, 6:29 AM ET
Gilead Receives EMA CHMP Recommendation For Authorization For Trodelvy Plus Keytruda To Treat Metastatic Triple-Negative Breast Cancer
Press releaseJul 24, 6:26 AM ETBusiness Wire
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
NewsJul 24, 6:25 AM ETStjepan Kalinic
Two Years to Build or Pay 200% — Which US Pharma Stocks Win?
NewsJul 6, 2:05 PM ETVandana Singh
Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says
NewsJun 25, 11:17 AM ETVandana Singh
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer
NewsMay 8, 1:36 PM ETPiero Cingari
Nasdaq Tops 29,000 Records, Micron Soars 13%: Stock Market Today
Press releaseMay 7, 4:01 PM ETBusiness Wire
Gilead Sciences Announces First Quarter Financial Results
NewsFeb 10, 4:05 PM ET
Gilead Sciences Increases Its Quarterly Cash Dividend From $0.79 To $0.82
Press releaseFeb 10, 4:02 PM ETBusiness Wire
Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
Press releaseFeb 10, 4:01 PM ETBusiness Wire
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
Press releaseOct 30, 4:02 PM ETBusiness Wire
Gilead Sciences Announces Third Quarter 2025 Financial Results
NewsAug 25, 3:47 PM ETJosh Enomoto
Options Corner: Why The Market Could Be Prescribing A Bull Call Spread For Gilead Sciences
Press releaseAug 7, 4:02 PM ETBusiness Wire
Gilead Sciences Announces Second Quarter 2025 Financial Results
NewsAug 7, 2:51 PM ETAvi Kapoor
How To Earn $500 A Month From Gilead Sciences Stock Ahead Of Q2 Earnings

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Gilead Bolsters Inflammatory Bowel Disease Pipeline With Promising Mid-Stage Trial Success

Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments

Vir Biotechnology Signs Up To $1.875B Gilead Deal For 3 Cancer Drug Candidates; Gilead To Pay $65M Cash Upfront And Buy 1,765,486 Shares At $14.16 Each, For A Total Of $25M, Plus Up To $1.785B In Milestones And Royalties

Vir Biotechnology Announces Collaboration, License Agreement With Gilead To Discover, Engineer Three PRO-XTEN Dual-Masked T-Cell Engager Development Candidates Targeting Selected Solid Tumor-Associated Antigens

Bill Clinton Sounds Alarm on HIV Funding: ‘Cheaper Medicines Mean Nothing If They Never Reach People’

10 Health Care Stocks Whale Activity In Today’s Session

Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention

ITOC Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against iTonic Holdings Ltd.

Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean

A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines

FDA Approves Gilead's New Single Tablet HIV Regimen

World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency

U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens

Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences

ITOC Stockholders Have Rights – If You Lost Money Investing in iTonic Holdings Ltd. Contact Robbins LLP for Information About Recovering Your Losses

10 Health Care Stocks Whale Activity In Today’s Session

European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status

Did You Lose Money Investing in iTonic Holdings Ltd.? Robbins LLP Urges Investors With Significant Losses to Contact the Firm for Information About Their Rights Against ITOC

KLA, Snowflake, Airbnb And A Health Care Stock On CNBC’s ‘Final Trades’

PTHL Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against iTonic Holdings Ltd. (ITOC)- Previously Knowns as Pheton Holdings Ltd. (PTHL)

Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'

Gilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

Gilead Sciences Announces Second Quarter 2026 Financial Results

Shareholder Alert: Robbins LLP Informs Shareholders of the iTonic Holdings Ltd. (ITOC)– Previously Known as Pheton Holdings Ltd. (PTHL)– Class Action Lawsuit

SpaceX Could Swing $204 Billion After Earnings

Eli Lilly Could Swing Over $76 Billion In Value After Earnings

4 Health Care Stocks With Whale Alerts In Today’s Session

Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial

Gilead Receives EMA CHMP Recommendation For Authorization For Trodelvy Plus Keytruda To Treat Metastatic Triple-Negative Breast Cancer

CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

Two Years to Build or Pay 200% — Which US Pharma Stocks Win?

Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says

Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer

Nasdaq Tops 29,000 Records, Micron Soars 13%: Stock Market Today

Gilead Sciences Announces First Quarter Financial Results

Gilead Sciences Increases Its Quarterly Cash Dividend From $0.79 To $0.82

Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend

Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results

Gilead Sciences Announces Third Quarter 2025 Financial Results

Options Corner: Why The Market Could Be Prescribing A Bull Call Spread For Gilead Sciences

Gilead Sciences Announces Second Quarter 2025 Financial Results

How To Earn $500 A Month From Gilead Sciences Stock Ahead Of Q2 Earnings